IgD, IgE, IgM in myeloma are each rare myelomas accounting for less than 1% of all cases and sometimes thought to have a worse prognosis than ''usual'' myelomas (IgG, IgA and light chain myeloma). Non-secretory (NS) myeloma is also an uncommon condition which has also been associated with a poor prognosis. We have used the EBMT Data Registry to study the survival of these patients treated with transplant strategies. Seventy-three IgD patients who had autologous transplantation were compared with 4905 patients with usual myelomas and were noted to have significantly higher B2M at diagnosis (p=0.006), more patients who received TBI in their conditioning regimen (p=0.005) and less responsive disease at the time of transplant (p=0.02).
The median survival post transplantation was 28 months compared with 52 months for the usual group (p=0.002). In contrast in the 174 NS (non M -protein producing) myelomas there were significantly more cases of stage III disease (p=0.02) but less TBI usage than in the usual myelomas (p=0.014). Median survival was 45 months (p=0.49) indicating the outlook for NS myeloma treated by transplantation is no different to usual myeloma. With regard to IgE (2 patients) and IgM (6 patients) there was insufficient data for statistical analysis although scrutiny of the data suggested that both IgE and IgM myelomas may have similar survival to IgD myeloma. Review of the allogenic database shows that 19 NS patients were transplanted with a median survival of 27 months which compares favourably with median survival for ''usual'' myelomas with allogenic transplantation of 26 months. In the 13 IgD myeloma patients with allogenic transplantation survival is very variable. Two IgM patients also had allogenic transplantation.
These results indicate that NS myeloma responds to transplantation therapy as if they were secretory (usual) myelomas while the confirmation of poor prognosis in IgD myeloma indicates the necessity to look for additional or alternative therapeutic strategies.
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Transplantation in plasma cell leukemia M. Drake, C. Morris, A. Hagman, B. Bjorkstrand, G. Gahrton, J. 
Apperley on behalf of Myeloma Subcommittee of Chronic Leukaemia Working Party
Primary plasma cell leukaemia (PCL) is an infrequent disorder, reportedly about 50 times less common than multiple myeloma (MM). Resulting from the expansion of immature plasma cells, the condition requires prompt and vigorous treatment, which has improved the poor response seen with standard alkylating agent based therapies. We report EBMT Registry data on a series of 56 patients with PCL and compare this with 5157 patients with MM undergoing autologous haemopoietic stem cell transplantation (HSCT). Patient groups were comparable with regard to gender and M protein at diagnosis. 1903/5157 MM patients and 24/56 PCL patients were Stage III at diagnosis (p = 0.1621) and disease status pre-transplantation was not significantly different. PCL patients had higher B2 microglobulin at diagnosis (p = 0.0002) and comprised a significantly younger group at time of transplant (median age 51 years v. 59 years, p = 0.04). Transplantation of PCL patients occurred earlier after diagnosis with median time from diagnosis of 7 months v. 8 months for MM patients, p = 0.006. Conditioning included TBI in 2653 (51.4%) of MM patients and 27 (48.2 %) of PCL patients (p = 0.8059). There was no difference between groups in the use of bone marrow, peripheral blood stem cells or a combination as source of HSC (p = 0.096). However, outcome after HSCT was significantly different between the groups, with median survival dramatically lower for PCL patients (26 months v. 51 months for MM patients) and high attrition in the 1st year post -transplant. Review of the allogenic transplant database shows 15 patients with PCL transplanted; their characteristics are similar to the autologous group but with a median survival of under 1 year. Treatment of PCL is often disappointing with only a subgroup of patients surviving initial therapy. High dose therapy offers significant long-term survival but outcomes are significantly worse than for comparable patients with myeloma, despite younger age and earlier transplantation from time of diagnosis. Further investigation of conditioning and supportive measures is necessary to improve the outlook in this aggressive disorder.
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Complete remission at transplant and in vitro purging of the graft translate into a better event-free and overall survival in multiple myeloma A. Barbui, M. Galli, A. Salvi, A. Rambaldi, T. Barbui (Bergamo, I) We report the results obtained in 60 newly diagnosed Multiple Myeloma (MM) patients who after high dose chemotherapy (VAD x 3, Cyclophosphamide, 7 gr/m2 + G -CSF 5 mcg/kg) were randomized to receive either unmanipulated (31 patients) or in vitro purged (29 patients) peripheral blood stem cells (PBSC) in a tandem autologous transplant program. Patient characteristics were as follows: 32/28 male/female; median age 56 years; stage II-A (n= 4) and stage III-A/B 49/7 patients. Median serum Beta 2 microglobulin (B2M) was 3 .45 mg/L (range 1.3-16.8), median calcemia was 9.4 mg/dL (range 7-14.7). Cytogenetic analysis was successfully performed in 29 patients. After each transplant the hematologic engraftment and the immunologic reconstitution were rapid and comparable in both arms and no transplant related mortality was observed. Minimal residual disease (MRD) before and after in vitro purging, was evaluated by Real Time (RT) PCR analysis. The unmanipulated aphereses contained a heavy plasma cell contamination and a significant (3-4 log) reduction of tumor cells was obtained by our in vitro purging technique. With a median follow-up of 30 months (range 11-61) the event free survival (EFS) and overall survival (OS) at three years is 44% and 87% in the control arm and 73% and 85% in the experimental arm. By a Cox time-dependent multivariate analysis, a reduced risk of disease progression was associated with being in CR at time of first transplantation (p= 0.003) and the use of a purged graft (p= 0.005). Interestingly, at three years the EFS of patients achieving early CR after VAD or high dose cyclophosphamide was 86% versus 44% of patients not achieving early CR (p= 0.004). Among these latter patients, (23 in the purged arm and 17 in the control) the role of purging appears to be even more important, since at three years the EFS was 62%, in patients transplanted with a purged graft versus 21% in patients transplanted with unmanipulated PBSC (p= 0.02). The achievement of CR at the time of transplantation also affected survival since OS at three years was 100% for patients achieveing CR as compared to 67% (p= 0.03) observed in patients not in CR before transplantation.
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Intensified conditioning therapy with total marrow irradiation, busulfan and cyclophosphamide followed by PBSCT results in a high CR rate and prolonged EFS in patients with advanced multiple myeloma H. Einsele, C. Meisner, C. Straka, H. Schmidt, H. Schmidberger, H. Hebart, L. Truemper, R. Mueller, G. Schlimok, B. Hertenstein, N. Kroeger, A.R. Zander, D. Peest, B. Metzner, W. Budach, N. Frickhofen, L. Kanz, M. Bamberg (Tuebingen, Munich, Hameln, Goettingen, Augsburg, Hannover, Hamburg, Oldenburg, Wiesbaden, D) The overall survival of patients with advanced multiple myeloma (MM) undergoing high-dose chemotherapy and autologous stem cell transplantation (SCT) was found to depend mainly on the quality of response. Thus, to improve the response rate, a new intensified high-dose chemoradiotherapy was evaluated in a phase I/II study. 89 patients (median age of 51, range 32 -60 years) received an intensified conditioning regimen consisting of total marrow irradiation (9 Gy applied in 2 fractions over 3 days with shielding of the lung and liver), high dose busulfan and cyclophosphamide 120 mg/kg (TMI/Bu/Cy) followed by PBSCT. Prior to chemoradiotherapy an induction and mobilization chemotherapy (4 g/m² cyclophophamide) were administered. Isotypes were IgG in 48, IgA in 23, Light chain disease in 14, IgD in 3 and a nonsecretory MM in 1 patient. Stage IIIA MM was diagnosed in 52, stage IIIB in 18, stage IIA in 16, stage IIB in 3 patients. 56 (62%) patients were pretreated at the time of inclusion in the study (35 with 1, 21 with > 1 line of pretreatment). 27 patients had received conventional therapy for > 1 year prior to high dose chemoradiotherapy. Regimen-related toxicity according to WHO criteria and response rates as defined by the EBMT/IBMTR criteria were analysed. TRM was 2% with 1 patient dying of invasive aspergillosis. Three patients developed reversible hepatic veno-occlusive disease (VOD). The main toxicity observed was mucositis WHO grade III/IV in 76%, and fever WHO grade > I in 75% of patients. Among the patients with de novo and pretreated MM a CR rate of 48% and 41%, respectively, was documented. With a median follow-up of 35 months, the actuarial median duration of progression-free survival (PFS) and overall survival (OS) of the whole patient group after transplant were 31 and 58 months, respectively and for patients with de novo MM 35 and > 60 months, respectively. Thus, administration of this new intensified conditioning regimen was associated with a tolerable toxicity and a high response rate. Due to these promising data, conditioning therapy with TMI/Bu/Cy is currently compared with tandem high dose melphalan in patients with advanced MM in a phase III study.
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Second high-dose melphalan autografts for myeloma patients relapsing after one autograft: results equivalent to tandem transplantation B. Sirohi, R. Powles, S. Singhal, J. Treleaven, S. Kulkarni, S. Sankpal, S. Goyal, C. Horton, J. Mehta (Sutton, UK) One of the potential treatment options available for myeloma patients relapsing after one autograft is another cycle of high-dose therapy and a second autograft. 96 patients (34-77 y, median 55) underwent second autografts (Tx2) after 200 mg/m² melphalan (HDM200) for myeloma relapsing after one autograft (Tx1). The intervals between Tx1 and Tx2, Txl and relapse, and Tx2 were 6 wks to 11.8 y (median 3.2 y), 3 mo to 8.8 y (median 2.1) and 1 wk to 7.4 y (median 10 months) respectively. 23 received marrow and 73 PBSCs. 49 patients had chemosensitive disease at the time Tx2 (6 CR,43 PR). 15 patients died of toxicity with Tx2. Amongst the 51 patients in whom the number of CD34+ cells infused was available, 0 of 13 patients receiving >0.9 c 106 CD34+ cells died of toxicity compared with 7 of 38 getting <0.9 (P=0.11). No other factor affected treatment-related mortality. 30 attained CR, 40 attained PR, 10 did not respond, and 2 patients have not been evaluated yet. The overall response rate was 74% (70 of 94). 56 patients experienced disease progression at a median of 10.5 mo. Overall, 33 patients are alive at the last follow-up 2 wks to 10.9 y after Tx2 (median 15 mo); 24 in continued CR/PR after Tx2 and 9 with disease progression. The actuarial 3 -y probabilities of relapse, disease-free survival and overall survival from Tx2 were 84%, 13% and 35% respectively. When adjusted for early deaths after Tx2, the following favorable factors were identified to be significant in Cox analysis: (a) Relapse: disease response after Tx2 (RR 0.25;P<0.0001); (b) EFS: disease response after Tx2 (RR 3.9; P<0.0001), beta2-microglobulin <=4 mg/dL (RR 2.3; P=0.01), and relapse >2 years after T x 1 (RR 1.7; after Tx1 (RR 1.9; P=0.02) and disease response after Tx2 (RR 2.5; P=0.04). For the 47 patients relapsing >2 y after Tx1 who had a beta2-M level <=4 mg/dL at Tx2, the 3-y probabilities of relapse, diseasefree survival and overall survival from Tx2 were 73%, 25%, and 51% respectively. From the time of Tx1, the actuarial survival of the group is 61% at 5 y and the median survival is 6.4 y. The latter is comparable to that reported with tandem autotransplantation suggesting that salvage autotransplantation at relapse produces results that are equivalent to those seen with tandem autografts. We conclude that HDM200 and a second autograft is a reasonable treatment option in selected patients relapsing after 1 autograft.
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High complete remission rate of tandem transplant consisting of autograft followed by dose-reduced allograft in patients with multiple myeloma N. Kröger, R. Schwerdtfeger, M. Kiehl, H. Sayer, H. Renges, T. Zabelina, B. Fehse, F. Tögel, G. Wittkowsky, R. Kuse, A. Zander (Wiesbaden, Idar-Oberstein, Jena, Hamburg, D) Purpose: To evaluate the toxicity, engraftment, chimerism, acute graft-versus host disease (GvHD) and response of a dosereduced allograft after cytoreductive autograft for patients with multiple myeloma (MM) . Patients and Methods: 14 patients with advanced stage II/III MM first received autografting after melphalan (200 mg/m²) followed by a dose-reduced regimen consisting of fludarabine (180 mg/m²), melphalan (100 mg/m²), ATG (3x10mg/kg) and allografting from related (n=7) or unrelated n=7) donors to induce a graft versus myeloma effect. The median interval between autologous and allogeneic transplantation was 119 days (range 60-210). Results: After dose-reduced allografting all patients became neutropenic ( < 0.2 x109/L) and required platelet transfusions. No graft failure was observed. The median time for leukocyte (>1 x 109/L) and platelet (>20 x 109/L) engraftment was 16 (range 13-22) and 24 days (range 14-43), respectively. Complete donor chimerism was detected in all patients after a median of 30 days (range 19 -38)post allografting. Acute GvHD occured in 4 patients (30%). Severe grade III GvHD was observed in two patients (15%). Two of nine evaluable patients developed chronic GvHD (22%). Grade II toxicity was primarily mucositis (50%) and liver toxicity (42%). One patient died with multiorgan failure after septicemia and pneumonia on day 22 after allogeneic transplantation. Overall transplant related mortality at day +100 was 7%. 70% achieved a complete remission (CR) with negative immunofixation and 4 patients have PR with still decreasing monoclonal bands. Conclusion: The tandem auto-allo-transplant-protocol provides rapid engraftment with complete donor chimerism, managable toxicity and low day +100 treatment related mortality. The high rate of CR is encouraging but a longer follow-up is needed to determine late mortality and late relapse.
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Allogeneic transplantation following relapse after autologous transplantation in multiple myeloma S. Hoepfner, I. Breitkreutz, T. Möhler, A. Benner, H. Goldschmidt, A. Ho, M. Görner (Heidelberg, D) Background: Although notable advances in therapy for multiple myeloma have been achieved, most patients relapse despite autologous stem cell transplantation. Unfortunately, survival is very limited after post-transplantation relapse, and chemotherapy is unable to establish long-term remission. Allogeneic transplantation offers a potential for cure but is also associated with high transplant-related morbidity and mortality (TRM). Nonmyeloablative transplantation has been shown to reduce TRM but the benefit for patients having relapsed after autologous transplatation has not yet been proven. Therefore, we performed a retrospective analysis comparing non-myeloablative transplantation versus conventional chemotherapy in this situation.
Patients and Methods: From 8/96 to 9/01 28 patients with relapsed MM were treated with conventional chemotherapy alone, whereas 16 received a related (n=10) or unrelated (n=6) allogeneic stem cell transplantation following induction chemotherapy. For conditioning, 3 patients received 2 Gy TBI alone, in the other patients fludarabin was combined with 2 Gy TBI. Posttransplant immunosuppression consisted of cyclosporine and MMF. In the chemotherapy group, patients were treated with varying regimens, including VAD, MP and dexamethasone. All relapsed patients received thalidomide, unsually in combination with cyclophosphamide (400mg/m²), etoposide (40mg/m²), dexamethasone (40mg). Both groups were well matched for age, initial disease stage, and time from diagnosis to relapse. Results: The median overall survival was 24 months in the allogeneic group compared to 22 months in the chemotherapy group. A Kaplan-Meier estimate of survival showed a 3year survival of 50% for both groups. When allogeneic transplantations from related versus unrelated donors were analyzed separately, patients who received grafts from a related donor had a prolonged survival expectancy of 70 % at 36 months, in contrast to 50 % for the chemo-group and 30 % for patients grafted from unrelated donors. Conclusion: Our results suggest a beneficial effect of allogeneic transplantation from a related donor after reduced intensity conditioning in patients relapsing after autologous transplantation. A prospective randomized study is needed to confirm this observation. In addition life-quality assesment is needed to define the role of allogeneic transplantation in this poor prognosis group of patients.
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An update of allogeneic transplantation with peripheral blood stem cells (PBSCT) as compared to bone marrow (BMT) in multiple myeloma
G. Gahrton, J. Apperley, A. Bacigalupo, B. Björkstrand, J. Bladé, M. Cavo, J. Cornelissen, A. De Laurenzi, T. Facon, A. Hagman, P. Ljungman, M. Michallet, D. Niederwieser, R. Powles, J. Reiffers, N. Russell, D. Samson, U. Schaefer, A. Schattenberg, S. Tura, L. Verdonck, J. Vernant, R. Willemze, L. Volin (Stockholm, S; London, UK; Genoa, I; Barcelona, E; Bologna, I; Rotterdam, NL; Rome, I; Lille, Lyon, F; Leipzig, D; Sutton, UK; Pessac, F; Nottingham, UK; Essen, D; Nijmegen, Utrecht, NL; Paris, F; Leiden, NL; Helsinki, FIN) Allogeneic transplantation with peripheral blood stem cells (PBSCT) has been increasingly performed in multiple myeloma at EBMT centers since 1994. So far PBSCT for multiple myeloma has not proven to be superior to bone marrow transplantation (BMT). In the present update in March 2001 of 521 allogeneic transplants (PBSCT: n=224; BM: n= 297) an attempt was made to compare results of PBSCT versus BMT as well as in prognostic subgroups. The two groups PBSCT and BMT were well matched for patient age, gender, stage at diagnoses, time from diagnosis to transplant, treatment lines before transplant and response to pretransplant regimens. However, the follow up time was significantly shorter for PBSCT, due to the increasing frequency of PBSCT with time. The overall response rate was similar in both groups (complete hematologic remission (CR): 54% and 55 % at 2 years respectively). Survival tended to be better in the BMT group (PBSCT: 44% and BMT: 53 % at 3 years; p = 0.05). Transplant related mortality was not significantly different (PBSCT: 33% and BMT: 28 % at 1 year; p = 0.14). Acute GVHD was similar in both groups (absent: 30 % and 36 %; grade I: 25% and 26 %; grade II: 30 % and 26 %; grade III/IV: 15% and 12%; p= 0.8). Chronic GVHD in the PBSCT and BMT groups respectively was 26% and 25% at 6 months, 38% and 33% at 12 months and 59% and 40% at 24 months. This difference was not statistically significant (p = 0.09). There was no significant difference in progression free survival or relapse rate.
Analysis of PBSCT versus BMT in subgroups i.e. high or low age, male or female, one or >one lines of therapy, responsive-no responsive, stage I/II-III indicated that PBSCT may be preferential for survival in patients diagnosed in stage I/II (p=0.06) with no significant difference in other subgroups. Thus, although overall survival tends to be superior following BMT, patients diagnosed in stage I/II seem to have a somewhat better survival with PBSCT with no significant difference between PBSCT and BMT in other subgroups.
Autoimmune Disease
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Autologous hematopoietic stem cell transplantation in secondary progressive MS: clinical, MRI and laboratory findings R. Saccardi, G. Mancardi, A. Bacigalupo, A. Bosi, P. Di Bartolomeo, A. Donelli, F. Gualandi, G. La Nasa, A. Murialdo, F. Pagliai, F. Papineschi, G. Saglio, A. Marmont (Florence, Genoa, Pescara, Modena, Cagliari, Pisa, Orbassano, I) In MS five phase I/II studies have been published, which demonstrate that AHSCT is feasible and is associated with a stabilization of the disease course in the majority of cases. Recently, a phase II study evaluating the effect of the treatment on MRI enhancing activity has been organized in Italy. 18 patients with secondary progressive MS, with EDSS between 5 and 6,5, unresponsive to conventional treatment and with clinical and radiological signs of active disease, were mobilized with CY 4 g/m2 followed by Filgrastim 5 µg/Kg; the ablative regimen was BEAM, followed by rabbit ATG (Thymoglobulin, Sangstat) 10 mg/Kg. Patients were then submitted to monthly MRI, for the first six months, then every three months until month 24, then every six months. Neurophysiological, neuropsychological tests and CSF examination were also performed. Mobilization was successful in all cases with a median number of CD34+ collected of 8,74 (3,51-26,02) . In one case, with a follow-up of 4 months, hemorrhagic cystitis occurred after mobilization. The conditioning regimen was well tolerated but infections were common. In 5 cases we observed a CMV reactivation in the first month after AHSCT. Immunological recovery after transplantation showed a prolonged decrease of circulating CD4+ count as compared to CD8+, thus resulting in a marked inversion of CD4+/CD8+ ratio up to one year. During the first year, a very low number of cells with a CD4+45RA+ phenotype was also detected. The median follow-up is now 18 months (range 2-42). The number of Gd positive areas dropped to 0 in 14 out of 16 cases in the months following the conditioning therapy. After 1 year there was a decrease of T2 total lesion load and volume of black holes of 8% and 19% respectively. Brain atrophy was still present and ongoing, but it appeared to slow after +180. At month 6 after AHSCT, patients developed multiple oligoclonal IgG bands (OB) in the serum, and many of them were also present in the CSF. After 12 and 24 months OB were still present in the serum and additional OB were detected in the CSF, but an accumulation of clonally related B cells, present before treatment, was no more detectable. Clinically patients were stable or slightly improved. The clinical efficacy has to be demonstrated in a phase III study, comparing ASCT to standard immunosuppressive therapy in order to assess if the clinical efficacy of AHSCT justifies the associated mortality and toxicity.
